カテゴリー： Transparency Market Research, 世界, 医療/バイオ

カルシウムチャネル遮断薬の世界市場2023～2031：薬剤クラス別、用途別、投与経路別

◆英語タイトル：Calcium Channel Blockers Market (Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine, Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others; Route of Administration: Oral and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが発行した調査報告書（TMR23JUL040）◆商品コード：TMR23JUL040
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2023年5月
◆ページ数：185
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米s、中東・アフリカ
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の当調査レポートでは、世界のカルシウムチャネル遮断薬市場規模が、2023年の145億ドルから2031年までに240億ドルに拡大し、予測期間中に年平均（CAGR）5.7%で成長すると推測しています。本書は、カルシウムチャネル遮断薬の世界市場について詳しく調査し、市場状況及び展望についてまとめています。序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤クラス別（フェニルアルキルアミン、ベンゾチゼピン、ジヒドロピリジン）分析、用途別（高血圧、扁桃炎、不整脈、肥大型心筋症、その他）分析、投与経路別（経口、非経口）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成で掲載しています。また、市場参入企業として、Pfizer, Inc.、Teva Pharmaceutical Industries Ltd.、Bausch Health Company, Inc.、Novartis AG、AstraZeneca、Merck & Co. Inc.、GSK plc、Bayer AG、Sun Pharmaceutical Industries Ltd.、Daiichi Sankyo Company, Limitedなどを含んでいます。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界のカルシウムチャネル遮断薬市場規模：薬剤クラス別
- フェニルアルキルアミンの市場規模
- ベンゾチゼピンの市場規模
- ジヒドロピリジンの市場規模
・世界のカルシウムチャネル遮断薬市場規模：用途別
- 高血圧における市場規模
- 扁桃炎における市場規模
- 不整脈における市場規模
- 肥大型心筋症における市場規模
- その他用途における市場規模
・世界のカルシウムチャネル遮断薬市場規模：投与経路別
- 経口投与における市場規模
- 非経口投与における市場規模
・世界のカルシウムチャネル遮断薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のカルシウムチャネル遮断薬市場規模：地域別
- 北米のカルシウムチャネル遮断薬市場規模
- ヨーロッパのカルシウムチャネル遮断薬市場規模
- アジア太平洋のカルシウムチャネル遮断薬市場規模
- 中南米のカルシウムチャネル遮断薬市場規模
- 中東・アフリカのカルシウムチャネル遮断薬市場規模
・競争状況

Calcium Channel Blockers Market – Scope of Report
TMR’s report on the global Calcium Channel Blockers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Calcium Channel Blockers market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Calcium Channel Blockers market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Calcium Channel Blockers market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Calcium Channel Blockers market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Calcium Channel Blockers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Calcium Channel Blockers market.

The report delves into the competitive landscape of the global Calcium Channel Blockers market. Key players operating in the global Calcium Channel Blockers market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Calcium Channel Blockers market profiled in this report.

Key Questions Answered in Global Calcium Channel Blockers Market Report
• What is the sales/revenue generated by Calcium Channel Blockers across all regions during the forecast period?
• What are the opportunities in the global Calcium Channel Blockers market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Calcium Channel Blockers Market – Research Objectives and Research Approach
The comprehensive report on the global Calcium Channel Blockers market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Calcium Channel Blockers market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Calcium Channel Blockers market.

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Calcium Channel Blockers Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Calcium Channel Blockers Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Disease Prevalence & Incidence Rate globally with key countries
    5.2. Key product/brand Analysis
    5.3. Pipeline Analysis
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Calcium Channel Blockers Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Class, 2017-2031
        6.3.1. Phenylalkylamine
        6.3.2. Benzothizepine
        6.3.3. Dihydropyridine
            6.3.3.1. 1st Generation
            6.3.3.2. 2nd Generation
            6.3.3.3. 3rd Generation
    6.4. Market Attractiveness Analysis, by Drug Class
7. Global Calcium Channel Blockers Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017-2031
        7.3.1. Hypertension
        7.3.2. Angina
        7.3.3. Arrhythmia
        7.3.4. Hypertrophic Cardiomyopathy
        7.3.5. Others (Raynaud’s disease, etc.)
    7.4. Market Attractiveness Analysis, by Application
8. Global Calcium Channel Blockers Market Analysis and Forecast, by Route of Administration
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Route of Administration, 2017-2031
        8.3.1. Oral
        8.3.2. Parenteral
    8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Calcium Channel Blockers Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017-2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Calcium Channel Blockers Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Calcium Channel Blockers Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017-2031
        11.2.1. Phenylalkylamine
        11.2.2. Benzothizepine
        11.2.3. Dihydropyridine
            11.2.3.1. 1st Generation
            11.2.3.2. 2nd Generation
            11.2.3.3. 3rd Generation
    11.3. Market Value Forecast, by Application, 2017-2031
        11.3.1. Hypertension
        11.3.2. Angina
        11.3.3. Arrhythmia
        11.3.4. Hypertrophic Cardiomyopathy
        11.3.5. Others (Raynaud’s disease, etc.)
    11.4. Market Value Forecast, by Route of Administration, 2017-2031
        11.4.1. Oral
        11.4.2. Parenteral
    11.5. Market Value Forecast, by Distribution Channel, 2017-2031
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Class
        11.7.2. By Application
        11.7.3. By Route of Administration
        11.7.4. By Distribution Channel
        11.7.5. By Country
12. Europe Calcium Channel Blockers Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017-2031
        12.2.1. Phenylalkylamine
        12.2.2. Benzothizepine
        12.2.3. Dihydropyridine
            12.2.3.1. 1st Generation
            12.2.3.2. 2nd Generation
            12.2.3.3. 3rd Generation
    12.3. Market Value Forecast, by Application, 2017-2031
        12.3.1. Hypertension
        12.3.2. Angina
        12.3.3. Arrhythmia
        12.3.4. Hypertrophic Cardiomyopathy
        12.3.5. Others (Raynaud’s disease, etc.)
    12.4. Market Value Forecast, by Route of Administration, 2017-2031
        12.4.1. Oral
        12.4.2. Parenteral
    12.5. Market Value Forecast, by Distribution Channel, 2017-2031
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Class
        12.7.2. By Application
        12.7.3. By Route of Administration
        12.7.4. By Distribution Channel
        12.7.5. By Country/Sub-region
13. Asia Pacific Calcium Channel Blockers Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017-2031
        13.2.1. Phenylalkylamine
        13.2.2. Benzothizepine
        13.2.3. Dihydropyridine
            13.2.3.1. 1st Generation
            13.2.3.2. 2nd Generation
            13.2.3.3. 3rd Generation
    13.3. Market Value Forecast, by Application, 2017-2031
        13.3.1. Hypertension
        13.3.2. Angina
        13.3.3. Arrhythmia
        13.3.4. Hypertrophic Cardiomyopathy
        13.3.5. Others (Raynaud’s disease, etc.)
    13.4. Market Value Forecast, by Route of Administration, 2017-2031
        13.4.1. Oral
        13.4.2. Parenteral
    13.5. Market Value Forecast, by Distribution Channel, 2017-2031
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Class
        13.7.2. By Application
        13.7.3. By Route of Administration
        13.7.4. By Distribution Channel
        13.7.5. By Country/Sub-region
14. Latin America Calcium Channel Blockers Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017-2031
        14.2.1. Phenylalkylamine
        14.2.2. Benzothizepine
        14.2.3. Dihydropyridine
            14.2.3.1. 1st Generation
            14.2.3.2. 2nd Generation
            14.2.3.3. 3rd Generation
    14.3. Market Value Forecast, by Application, 2017-2031
        14.3.1. Hypertension
        14.3.2. Angina
        14.3.3. Arrhythmia
        14.3.4. Hypertrophic Cardiomyopathy
        14.3.5. Others (Raynaud’s disease, etc.)
    14.4. Market Value Forecast, by Route of Administration, 2017-2031
        14.4.1. Oral
        14.4.2. Parenteral
    14.5. Market Value Forecast, by Distribution Channel, 2017-2031
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Class
        14.7.2. By Application
        14.7.3. By Route of Administration
        14.7.4. By Distribution Channel
        14.7.5. By Country/Sub-region
15. Middle East & Africa Calcium Channel Blockers Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Drug Class, 2017-2031
        15.2.1. Phenylalkylamine
        15.2.2. Benzothizepine
        15.2.3. Dihydropyridine
            15.2.3.1. 1st Generation
            15.2.3.2. 2nd Generation
            15.2.3.3. 3rd Generation
    15.3. Market Value Forecast, by Application, 2017-2031
        15.3.1. Hypertension
        15.3.2. Angina
        15.3.3. Arrhythmia
        15.3.4. Hypertrophic Cardiomyopathy
        15.3.5. Others (Raynaud’s disease, etc.)
    15.4. Market Value Forecast, by Route of Administration, 2017-2031
        15.4.1. Oral
        15.4.2. Parenteral
    15.5. Market Value Forecast, by Distribution Channel, 2017-2031
        15.5.1. Hospital Pharmacies
        15.5.2. Retail Pharmacies
        15.5.3. Online Pharmacies
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Drug Class
        15.7.2. By Application
        15.7.3. By Route of Administration
        15.7.4. By Distribution Channel
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company, 2022
    16.3. Company Profiles
        16.3.1. Pfizer, Inc.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Teva Pharmaceutical Industries Ltd.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Bausch Health Company, Inc.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Novartis AG
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. AstraZeneca
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Merck & Co. Inc.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. GSK plc
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Bayer AG
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Sun Pharmaceutical Industries Ltd.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Daiichi Sankyo Company, Limited
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview

List of Tables

Table 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 02. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 03. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 04. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 05. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 06. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 07. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 08. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 09. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 10. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 11. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 12. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 13. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 14. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 15. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 16. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 17. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 18. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 19. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 20. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 21. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 22. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 23. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 24. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 25. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 26. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 27. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 28. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 29. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 30. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ カルシウムチャネル遮断薬の世界市場2023～2031：薬剤クラス別、用途別、投与経路別(Calcium Channel Blockers Market (Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine, Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others; Route of Administration: Oral and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 抗感染症薬の世界市場2023～2031：薬剤クラス別、投与経路別
  • 世界の増殖糖尿病網膜症市場2023-2031：薬剤クラス別（抗VEGF薬、副腎皮質ステロイド薬）、投与形態別（注射剤、経口剤、その他）
  • 世界の頭頸部がん市場2023-2031：薬剤クラス別（EFGR阻害剤、分裂阻害剤、抗PD-1モノクローナル抗体、その他）、流通チャネル別（病院薬局、小売薬局、Eコマース）
  • 世界のアルツハイマー病に伴う認知症市場2023-2031：薬剤クラス別（コリン作動性/コリンエステラーゼ阻害薬、メマンチン、配合剤、その他）、流通チャネル別（病院薬局、小売店、オンライン販売）
  • 世界の乾癬性関節炎治療薬市場2022年ｰ2031年：薬効クラス別（TNF阻害剤、インターロイキン阻害剤、PDE4阻害剤、その他）、投与経路別

    • ◆H&Iグローバルリサーチのお客様（例）◆